Pathogenesis of calcineurin inhibitor-induced hypertension

Journal of Nephrology

Volumn 25, Issue 3, 2012, Pages 269-275

  Hoorn, Ewout J ^a   Walsh, Stephen B ^b   McCormick, James A ^c   Zietse, Robert ^a   Unwin, Robert J ^b   Ellison, David H ^c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cyclosporine; Sodium chloride cotransporter; Tacrolimus; Vasoconstriction; WNK kinase

Indexed keywords

AZATHIOPRINE; BUMETANIDE; CALCINEURIN INHIBITOR; CYCLOSPORIN; ENDOTHELIN; EPLERENONE; FLUDROCORTISONE; LITHIUM; NITRIC OXIDE; PHENYLEPHRINE; PROTEIN KINASE; PROTEIN KINASE SPAK; PROTEIN KINASE WNK; SODIUM CHLORIDE COTRANSPORTER; TACROLIMUS; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

BLOOD VESSEL FUNCTION; DRUG EFFECT; HUMAN; HYPERTENSION; HYPOALDOSTERONISM; KIDNEY FUNCTION; NEPHROTOXICITY; NERVOUS SYSTEM FUNCTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SODIUM RETENTION; SYMPATHETIC INNERVATION; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; CALCINEURIN; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TUBULES; RENIN-ANGIOTENSIN SYSTEM; SODIUM; SODIUM CHLORIDE SYMPORTERS; SYMPATHETIC NERVOUS SYSTEM; VASOCONSTRICTION; VASODILATION;

EID: 84863309114     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000174     Document Type: Review

References (65)

1. Nishiyama T, Yoshizaki N, Kishimoto T, Ohsumi K. Transient activation of calcineurin is essential to initiate embryonic development in Xenopus laevis. Nature. 2007;449(7160):341-345.
2. Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med. 2000;2(4):1-23.
3. Marks AR. Cellular functions of immunophilins. Physiol Rev. 1996;76(3):631-649.
4. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis. 2004;43(6):1071-1081.
5. Chatzikyrkou C, Menne J, Gwinner W, et al. Pathogenesis and management of hypertension after kidney transplantation. J Hypertens. 2011;29(12):2283-2294.
6. Marasà M, Remuzzi G, Cravedi P. Hypertension after kidney transplantation: an important, but still neglected issue. J Hypertens. 2011;29(12):2310-2311.
7. Textor SC, Canzanello VJ, Taler SJ, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc. 1994;69(12):1182-1193.
8. Jain A, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg. 1999;230(3):441-449 [discussion: 448-449].
9. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;(1):CD007893.
10. Yang SS, Lo YF, Wu CC, et al. SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. J Am Soc Nephrol. 2010;21(11):1868-1877.
11. Mu S, Shimosawa T, Ogura S, et al. Epigenetic modulation of the renal o-adrenergic-WNK4 pathway in salt-sensitive hypertension. Nat Med. 2011;17(5):573-580.
12. Schoeber JP, van de Graaf SF, Lee KP, Wittgen HG, Hoenderop JG, Bindels RJ. Conditional fast expression and function of multimeric TRPV5 channels using Shield-1. Am J Physiol Renal Physiol. 2009;296(1):F204-F211.
13. Klein IH, Abrahams AC, van Ede T, Oey PL, Ligtenberg G, Blankestijn PJ. Differential effects of acute and sustained cyclosporine and tacrolimus on sympathetic nerve activity. J Hypertens. 2010;28(9):1928-1934.
14. Kaye D, Thompson J, Jennings G, Esler M. Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation. 1993;88(3):1101-1109.
15. Murray BM, Paller MS, Ferris TF. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int. 1985;28(5):767-774.
16. Cavarape A, Endlich K, Feletto F, Parekh N, Bartoli E, Steinhausen M. Contribution of endothelin receptors in renal microvessels in acute cyclosporine-mediated vasoconstriction in rats. Kidney Int. 1998;53(4):963-969.
17. Lanese DM, Conger JD. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J Clin Invest. 1993;91(5):2144-2149.
18. Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol. 1990;1(1):76-83.
19. Textor SC, Burnett JC Jr, Romero JC, et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 1995;47(5):1426-1433.
20. Takeda Y, Miyamori I, Furukawa K, Inaba S, Mabuchi H. Mechanisms of FK 506-induced hypertension in the rat. Hypertension. 1999;33(1):130-136.
21. Takeda Y, Miyamori I, Wu P, Yoneda T, Furukawa K, Takeda R. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension. 1995;26(6 Pt 1):932-936.
22. Forslund T, Hannonen P, Reitamo S, Fyhrquist F. Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels. J Intern Med. 1995;238(1):71-75.
23. Gaston RS. Chronic calcineurin inhibitor nephrotoxicity: reflections on an evolving paradigm. Clin J Am Soc Nephrol. 2009;4(12):2029-2034.
24. Sturrock ND, Lang CC, Struthers AD. Cyclosporin-induced hypertension precedes renal dysfunction and sodium retention in man. J Hypertens. 1993;11(11):1209-1216.
25. Richards NT, Poston L, Hilton PJ. Cyclosporine A inhibits relaxation but does not induce vasoconstriction in human subcutaneous resistance vessels. J Hypertens. 1989;7(1):1-3.
26. Roullet JB, Xue H, McCarron DA, Holcomb S, Bennett WM. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J Clin Invest. 1994;93(5):2244-2250.
27. Morris ST, McMurray JJ, Rodger RS, Farmer R, Jardine AG. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int. 2000;57(3):1100-1106.
28. Marumo T, Nakaki T, Hishikawa K, Suzuki H, Kato R, Saruta T. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. Hypertension. 1995;25(4 Pt 2):764-768.
29. Basset EA, Berthoux P, Cécillon S, et al. Hypertension after renal transplantation and polymorphism of genes involved in essential hypertension: ACE, AGT, AT1 R and ecNOS. Clin Nephrol. 2002;57(3):192-200.
30. Lassila M. Interaction of cyclosporine A and the renin-angiotensin system; new perspectives. Curr Drug Metab. 2002;3(1):61-71.
31. Ciresi DL, Lloyd MA, Sandberg SM, Heublein DM, Edwards BS. The sodium retaining effects of cyclosporine. Kidney Int. 1992;41(6):1599-1605.
32. Kurtz A, Della Bruna R, Kühn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int. 1988;33(5):947-953.
33. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med. 1988;85(2):134-138.
34. Edwards BD, Chalmers RJ, O'Driscoll J, Lawson RS, Testa HJ, Ballardie FW. Modulation of abnormalities in renal haemodynamics and vasoactive mediators by nifedipine in patients with psoriasis on low-dose cyclosporin. Nephrol Dial Transplant. 1993;8(10):1071-1078.
35. Deppe CE, Heering PJ, Viengchareun S, Grabensee B, Farman N, Lombès M. Cyclosporine a and FK506 inhibit transcriptional activity of the human mineralocorticoid receptor: a cell-based model to investigate partial aldosterone resistance in kidney transplantation. Endocrinology. 2002;143(5):1932-1941.
36. Heering PJ, Kurschat C, Vo DT, Klein-Vehne N, Fehsel K, Ivens K. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression. Clin Transplant. 2004;18(2):186-192.
37. Nielsen FT, Jensen BL, Marcussen N, Skøtt O, Bie P. Inhibition of mineralocorticoid receptors with eplerenone alleviates short-term cyclosporin A nephrotoxicity in conscious rats. Nephrol Dial Transplant. 2008;23(9):2777-2783.
38. Nishiyama A, Kobori H, Fukui T, et al. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension. 2003;42(4):754-760.
39. Avdonin PV, Cottet-Maire F, Afanasjeva GV, Loktionova SA, Lhote P, Ruegg UT. Cyclosporine A up-regulates angiotensin II receptors and calcium responses in human vascular smooth muscle cells. Kidney Int. 1999;55(6):2407-2414.
40. Niehof M, Borlak J. HNF4alpha dysfunction as a molecular rational for cyclosporine induced hypertension. PLoS ONE. 2011;6(1):e16319.
41. Golbaekdal K, Nielsen CB, Pedersen EB. The acute effects of FK-506 on renal haemodynamics, water and sodium excretion and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide and vasopressin in pigs. J Pharm Pharmacol. 1996;48(11):1174-1179.
42. Nankivell BJ, Chapman JR, Bonovas G, Gruenewald SM. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation. 2004;77(9):1457-1459.
43. Textor SC, Wiesner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993;55(6):1332-1339.
44. Artz MA, Boots JM, Ligtenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol. 2003;14(7):1880-1888.
45. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant. 2004;4(6):937-945.
46. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci USA. 1985;82(23):8222-8226.
47. Zhang W, Li JL, Hosaka M, et al. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci USA. 2000;97(17):9765-9770.
48. Schlaich MP, Grassi G. Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander? J Hypertens. 2010;28(9):1809-1810.
49. Magina S, Santos J, Coroas A, et al. Salt sensitivity of blood pressure in patients with psoriasis on ciclosporin therapy. Br J Dermatol. 2005;152(4):773-776.
50. Damiano S, Scanni R, Ciarcia R, Florio S, Capasso G. Regulation of sodium transporters in the kidney during cyclosporine treatment. J Nephrol. 2010;23(Suppl 16):S191-S198.
51. Canzanello VJ, Textor SC, Taler SJ, et al. Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation. J Am Soc Nephrol. 1995;5(11):1910-1917.
52. Esteva-Font C, Ars E, Guillen-Gomez E, et al. Ciclosporininduced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2). Nephrol Dial Transplant. 2007;22(10):2810-2816.
53. Mohebbi N, Mihailova M, Wagner CA. The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. Am J Physiol Renal Physiol. 2009;297(2):F499-F509.
54. Aker S, Heering P, Kinne-Saffran E, Deppe C, Grabensee B, Kinne RK. Different effects of cyclosporine a and FK506 on potassium transport systems in MDCK cells. Exp Nephrol. 2001;9(5):332-340.
55. Wang J, Zhang ZR, Chou CF, Liang YY, Gu Y, Ma HP. Cyclosporine stimulates the renal epithelial sodium channel by elevating cholesterol. Am J Physiol Renal Physiol. 2009;296(2): F284-F290.
56. Hoorn EJ, Walsh SB, McCormick JA, et al. The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011;17(10):1304-1309.
57. Hadchouel J, Delaloy C, Fauré S, Achard JM, Jeunemaitre X. Familial hyperkalemic hypertension. J Am Soc Nephrol. 2006;17(1):208-217.
58. Wilson FH, Disse-Nicodème S, Choate KA, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001;293(5532):1107-1112.
59. Colussi G, Bettinelli A, Tedeschi S, et al. A thiazide test for the diagnosis of renal tubular hypokalemic disorders. Clin J Am Soc Nephrol. 2007;2(3):454-460.
60. Melnikov S, Mayan H, Uchida S, Holtzman EJ, Farfel Z. Cyclosporine metabolic side effects: association with the WNK4 system. Eur J Clin Invest. 2011;41(10):1113-1120.
61. McCormick JA, Mutig K, Nelson JH, et al. A SPAK isoform switch modulates renal salt transport and blood pressure. Cell Metab. 2010;14(3):352-364.
62. Calò LA. Vascular tone control in humans: insights from studies in Bartter's/Gitelman's syndromes. Kidney Int. 2006;69(6):963-966.
63. Paver WK, Pauline GJ. Hypertension and hyperpotassaemia without renal disease in a young male. Med J Aust. 1964;2:305-306.
64. Ellison DH, Brooks VL. Renal nerves, WNK4, glucocorticoids, and salt transport. Cell Metab. 2011;13(6):619-620.
65. Hoorn EJ, Walsh SB, Unwin RJ, Ellison DH. Hypertension after kidney transplantation: calcineurin inhibitors increase salt-sensitivity. J Hypertens. 2012;30(4):832-833.